Further development of this family of benzamide HDAC inhibitors identified three other pimelic o-aminobenzamide compounds, 106 (N1-(2-aminophenyl)-N7-p-tolylheptanediamide), 136 (N-(6-(2-amino-4-fluorophenylamino)-6-oxyhexyl)-4-methylbenzamide) and 109 (N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide), which have each undergone investigations to determine pharmacokinetic properties, safety and efficacy in short-term treatments of FRDA patient cells and mice (Chou et al., 2008; Rai et al., 2010, 2008; Soragni et al., 2008; Xu et al., 2009). The gene discussed is HDAC9; the disease is Friedreich ataxia.